Share on LinkedInShare on LinkedIn

ARTICLE · 08 APRIL 2015

Applicant’s Conduct That Does Not Actually Delay Prosecution Can Reduce Patent Term Adjustment

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In Gilead Sciences, Inc. v. Lee, No. 14-1159 (Fed. Cir. Feb. 26, 2015), the Federal Circuit held that the PTO reasonably interpreted 35 U.S.C. § 154(b)(2)(C) to reduce patent term adjustment ("PTA") for a patent based on the filing of a supplemental information disclosure statement ("IDS") after a response to a restriction requirement.

United StatesIntellectual Property

In Gilead Sciences, Inc. v. Lee, No. 14-1159 (Fed. Cir. Feb. 26, 2015), the Federal Circuit held that the PTO reasonably interpreted 35 U.S.C. § 154(b)(2)(C) to reduce patent term adjustment ("PTA") for a patent based on the filing of a supplemental information disclosure statement ("IDS") after a response to a restriction requirement.

Gilead Sciences, Inc. ("Gilead") owns U.S. Patent No. 8,148,374 ("the '374 patent") covering the compound cobicistat, an HIV drug.  During the prosecution of the application that led to the '374 patent, Gilead filed an IDS fifty-seven days after responding to an initial restriction requirement issued by the PTO.  In issuing the '374 patent, the PTO determined that Gilead was entitled to a PTA of 559 days, accounting for, inter alia, the reduction by an applicant-induced delay of the period between Gilead's initial reply to the restriction requirement and its filing of the IDS, according to 35 U.S.C. § 154(b)(2)(C)(i), which states

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from